Welcome to Dividends Inside
Welcome to Dividends Inside!

The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.

MoonLake Immunotherapeutics

MLTX
$17.05 (+ $0.68 + 4.15%)
Last updated: 2026-05-21 00:26 UTC
MLTX Metrics
Exchange
🇺🇸 NASDAQ XNCM
Nasdaq Capital MarketUnited StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINKY61559X1045
Market Price17.05
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-3.33
Market Cap$982.7M
Book Value4.54
Price to Book3.058
Beta1.21
52w High62.75
52w Low5.95
Next Earnings DateN/A
About the Company
MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Price History